McKesson Corporation

Report azionario NYSE:MCK

Capitalizzazione di mercato: US$94.3b

McKesson Performance degli utili passati

Criteri Il passato verificati 5/6

McKesson ha registrato una crescita degli utili a un tasso medio annuo di 44.3%, mentre il settore Healthcare ha registrato utili in crescita a un tasso medio annuo di 4%. I ricavi sono stati in crescita a un tasso medio annuo di 10.7%.

Informazioni chiave

44.32%

Tasso di crescita degli utili

45.18%

Tasso di crescita dell'EPS

Healthcare Crescita del settore8.50%
Tasso di crescita dei ricavi10.74%
Rendimento del capitale proprion/a
Margine netto1.18%
Ultimo aggiornamento sugli utili31 Mar 2026

Aggiornamenti sulle prestazioni recenti

Recent updates

Aggiornamento della narrazione • Jun 06

MCK: Medical Surgical Spin Off And Biosimilar Manufacturing Will Shape Future Haven Appeal

McKesson's analyst price target has been trimmed by about $2 to $949.73 as analysts recalibrate their fair value and future P/E assumptions following a recent cluster of target cuts and one increase across major research firms. Analyst Commentary Bullish Takeaways Bullish analysts have recently lifted their targets in some cases, suggesting they still see upside potential relative to current execution and long term growth initiatives.
Aggiornamento della narrazione • May 13

MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal

Analysts have trimmed the McKesson fair value estimate by about $39 to $951.73. This reflects updated views on slightly higher discount rates, a more moderate revenue growth outlook, a small shift in profit margin assumptions, and a lower future P/E multiple after a mix of recent price target increases and cuts across the Street.
Articolo di analisi • May 11

McKesson Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

McKesson Corporation ( NYSE:MCK ) shareholders are probably feeling a little disappointed, since its shares fell 8.9...
Seeking Alpha • May 01

McKesson - "Hold" Still Valid In 2026

Summary McKesson (MCK) is a fundamentally strong, market-leading distributor but faces mounting structural risks in the US healthcare sector. I see current valuation—over 21x P/E—as unattractive, with upside limited by regulatory, pricing, and margin pressures. Much of MCK's recent growth stems from high-priced drugs and GLP-1 revenues, which may plateau and expose underlying business vulnerabilities. I assign MCK a 'Hold' rating with a $510/share price target, citing insufficient risk/reward at present levels. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 27

MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal

McKesson's analyst price target has been trimmed slightly, with the fair value estimate edging down by about $1 to $990.87 as analysts factor in recent target cuts alongside ongoing interest in the company's biosimilar and distribution opportunities. Analyst Commentary Recent research on McKesson has centered on how much value the market is assigning to its biosimilar pipeline, distribution scale and perceived defensiveness within healthcare, with a mix of higher and lower price targets reflecting different views on execution risk and current valuation.
Aggiornamento della narrazione • Apr 10

MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Safe Haven Appeal

McKesson's analyst-derived fair value estimate has been adjusted slightly lower, from about $997.67 to $991.67. Analysts are weighing recent trims to Street price targets and fresh caution around premium valuation against prior enthusiasm for biosimilar optionality and healthcare defensiveness.
Aggiornamento della narrazione • Mar 27

MCK: Biosimilar And Co Manufacturing Upside Will Shape Future Safe Haven Returns

Analysts have nudged the McKesson fair value estimate slightly higher to about $998, citing a wave of Street price target increases into the $1,040 to $1,050 range and growing focus on potential upside from biosimilars and co-manufacturing. Analyst Commentary Recent Street research around McKesson clusters around two themes: valuation and execution on new growth levers such as biosimilars and co-manufacturing.
Aggiornamento della narrazione • Mar 11

MCK: Biosimilar Optionality And Premium Safe Haven Position Will Shape Future Returns

Analysts have increased their McKesson price target from $980.40 to $995.27, citing higher Street targets that reflect new biosimilar optionality and continued interest in the stock as a perceived healthcare safe haven, even at a premium valuation. Analyst Commentary Bullish analysts are leaning into McKesson's role as a perceived healthcare safe haven and the new biosimilar angle, using these themes to justify higher valuation levels than the recent three year average.
Aggiornamento della narrazione • Feb 24

MCK: Defensive Healthcare Premium And Buybacks Will Shape Perceived Safety Trade

Analysts have raised McKesson's fair value estimate by about $14 to $980.40, as a series of higher Street price targets, including Barclays' move to $1,050, keeps the stock in focus for investors seeking perceived safety within healthcare, even as shares trade at a premium to recent averages. Analyst Commentary Recent research has centered on McKesson's valuation after a series of price target increases, including a move to US$1,050 that highlights how closely investors are watching the name as a perceived defensive healthcare holding.
Aggiornamento della narrazione • Feb 09

MCK: Refined Assumptions And Supportive Policy Backdrop Will Shape FY26 AOI

The McKesson analyst price target has been raised by about $24 to $966, with analysts pointing to updated fair value work, modest adjustments to the discount rate and growth assumptions, and slightly higher future P/E expectations as key drivers of the change. Analyst Commentary Recent Street research on McKesson clusters around higher price targets and refreshed valuation work, with analysts fine tuning assumptions on growth, discount rates and future P/E multiples.
Aggiornamento della narrazione • Jan 26

MCK: North American Pharma Momentum And Supportive Policy Backdrop Will Drive FY26 AOI

Narrative Update The analyst price target for McKesson has been raised by roughly $3 to $942.00, as analysts point to steady assumptions for revenue growth, margins and P/E, along with supportive views on North American Pharma momentum, a constructive industry demand backdrop, and the absence of new onerous proposals in recent healthcare policy commentary. Analyst Commentary Recent research on McKesson is broadly constructive, with several firms lifting their price targets and pointing to supportive sector trends and company specific drivers.
Aggiornamento della narrazione • Jan 12

MCK: North American Pharma Strength Will Support FY26 Core AOI Framework

Narrative Update: McKesson Analysts have lifted their McKesson price targets toward a range of about $900 to $1,000, citing solid North American Pharma momentum, modeled core AOI growth of around 7% for FY26, and a robust demand backdrop reflected in peers' recent results. Analyst Commentary Recent research updates reflect a more constructive stance on McKesson, with higher price targets tied to underlying business trends and peer readthroughs rather than short term trading factors.
Aggiornamento della narrazione • Dec 18

MCK: North American Pharma Momentum Will Drive Future EPS Framework Confidence

Our McKesson narrative fair value has increased modestly to approximately $939 per share from about $935, reflecting analysts' higher price targets and conviction in sustained EPS growth, improved North American Pharma momentum, and a more robust valuation framework supported by stronger industry demand trends. Analyst Commentary Street research sentiment on McKesson remains skewed positive, with a broad wave of price target increases reflecting higher conviction in the companys ability to deliver on its upgraded long term earnings framework and FY26 guidance.
Aggiornamento della narrazione • Dec 03

MCK: North American Pharma Momentum Will Drive Future Outlook Amid Policy Uncertainty

We modestly raise our McKesson fair value estimate to about $934.79 per share from roughly $934.71, reflecting analysts' higher price targets, stronger confidence in long term EPS growth, and sustained North American Pharma momentum. Analyst Commentary Street research on McKesson has turned increasingly constructive, with multiple firms lifting price targets in response to upgraded long term guidance, stronger segment momentum, and enhanced disclosure following the recent investor day.
Aggiornamento della narrazione • Nov 19

MCK: Future Execution and Pharma Trends Will Shape Outlook Amid Policy Uncertainty

McKesson's analyst price target has been raised significantly, increasing by nearly $90 per share to $934.71. Analysts cite strong momentum in North American Pharma, higher long-term EPS guidance, and robust industry trends supporting continued growth.
Aggiornamento della narrazione • Nov 05

MCK: Future Demand and Oncology Distribution Will Set the Earnings Outlook

McKesson’s analyst price target has increased from approximately $837 to $845. Analysts cite robust demand, industry-wide utilization trends, and the company’s strengthened long-term earnings outlook as key factors supporting the upward revision.
Aggiornamento della narrazione • Oct 22

Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments

Analysts have raised their average fair value estimate for McKesson to $836.71 from $829.57. This change is attributed to increased long-term growth guidance and improved business visibility following the company’s recent investor day.
Aggiornamento della narrazione • Oct 08

Pharmaceutical Demand And Digital Automation Will Shape Future Markets

McKesson's analyst fair value estimate has been raised from $793.21 to $829.57. This increase reflects higher price targets, driven by analysts who cite upgraded long-term growth guidance and strengthened expectations following recent investor presentations.
Aggiornamento della narrazione • Sep 24

Pharmaceutical Demand And Digital Automation Will Shape Future Markets

McKesson’s fair value saw only a marginal increase as analyst expectations for both revenue growth and net profit margin remained virtually unchanged, with the target price moving slightly from $788.57 to $793.21. What's in the News Playhouse MD™, a pediatric healthcare brand, has entered a strategic distribution alliance with McKesson Medical-Surgical, making its products available nationwide and expanding McKesson's portfolio in pediatric care.
Articolo di analisi • Jul 07

Why Investors Shouldn't Be Surprised By McKesson Corporation's (NYSE:MCK) P/E

With a price-to-earnings (or "P/E") ratio of 27.3x McKesson Corporation ( NYSE:MCK ) may be sending bearish signals at...
Seeking Alpha • Mar 25

McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025

Summary I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs and geopolitical tensions ensures stability, making it a reliable investment amid economic uncertainties. The company's GLP-1 and oncology franchises are key growth drivers, with GLP-1 revenue growing 45% year-over-year and oncology patient visits increasing steadily. Despite potential tariff-related risks in the biotech sector, McKesson's strong performance and strategic guidance make it a safe haven for investors in 2025. Read the full article on Seeking Alpha
Seeking Alpha • Jan 21

McKesson Seems Cheap, But Risks Linger

Summary McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow, despite recent price increases and solid growth prospects in oncology and GLP-1 medications. Quarterly results show mixed performance, with revenue up 21.3% YoY but operating income and EPS down; adjusted EPS grew 13.5% YoY. Risks include political pressures on drug pricing, competition from vertically integrated healthcare providers like CVS and Amazon, and potential recession impacts. Despite bullish arguments and recession resilience, I rate McKesson as a 'Hold' due to high recession risk and a cautious market outlook. Read the full article on Seeking Alpha
Seeking Alpha • Nov 09

McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network

Summary I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in Florida Cancer Specialists enhances its oncology network, expanding to 3,300 providers across 31 states. Strong Q2 results with 21% revenue growth and raised EPS guidance to $32.40-$33.00, driven by specialty distribution and retail national account customers. Future growth driven by GLP-1 medications, oncology network expansion, and margin improvements, despite weak growth in Medical surgical solutions post-Covid. Read the full article on Seeking Alpha
Seeking Alpha • Oct 09

McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff

Summary Healthcare is a great defensive sector that has lower amounts of cyclicality than others that depend on the booming economy. With the stock currently down -21.44% off of its all-time high, the stock is giving investors a nice entry point as it reverts to the mean S&P500 returns. The company was the highest-scoring large cap on the most recent Magic Formula screen for October 2024. The Healthcare distribution sub-sector provides exposure to big Pharma without the patent cliffs. Read the full article on Seeking Alpha
Seeking Alpha • Sep 10

McKesson: The Correction Is Not Over

Summary McKesson declined about 20% in the last few weeks and sentiment suddenly turned. Of course, McKesson is performing hand-in-hand with the overall market and we can expect that McKesson will continue to decline - similar to the overall market. On the other hand, we can argue that McKesson is already undervalued a bit, but I still think the stock will continue to decline further due to the overall sentiment. Read the full article on Seeking Alpha
Seeking Alpha • Jul 04

McKesson Corporation: An Interesting Health Giant With A Hidden Gem

Summary McKesson Corporation is a large player in the medical space, with a market capitalization of $75.86 billion. The company has shown attractive top-line growth, but bottom-line results have been disappointing. The most interesting segment of the business is the Prescription Technology Solutions segment, showing impressive growth and profitability. Read the full article on Seeking Alpha

Ripartizione dei ricavi e delle spese

Come McKesson guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NYSE:MCK Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
31 Mar 26403,4304,7628,2390
31 Dec 25397,9584,3408,3620
30 Sep 25387,0944,0337,3310
30 Jun 25377,5953,1648,1180
31 Mar 25359,0513,2957,9980
31 Dec 24344,5832,8268,0310
30 Sep 24330,1872,5368,7550
30 Jun 24313,7512,9598,1130
31 Mar 24308,9513,0028,0100
31 Dec 23301,5062,9987,8090
30 Sep 23291,0983,4877,9720
30 Jun 23284,0403,7557,8810
31 Mar 23276,7113,5637,9140
31 Dec 22273,9033,1468,2580
30 Sep 22272,0272,0618,4380
30 Jun 22268,4461,3968,7020
31 Mar 22263,9661,1198,9370
31 Dec 21257,0061,4158,9180
30 Sep 21250,991-4,8048,9260
30 Jun 21245,223-4,4948,9190
31 Mar 21238,228-4,5388,7910
31 Dec 20237,621-4,1898,6960
30 Sep 20234,1942,2288,8750
30 Jun 20231,0029228,8640
31 Mar 20231,0519068,9070
31 Dec 19224,945-9059,64171
30 Sep 19221,981-6269,16071
30 Jun 19217,4406018,64271
31 Mar 19214,319338,4370
31 Dec 18213,518-3198,362125
30 Sep 18210,9271138,197125
30 Jun 18209,913-3848,300125
31 Mar 18208,357628,138125
31 Dec 17205,4424,8057,464341
30 Sep 17201,9554,5397,503341
30 Jun 17199,8514,8467,317341
31 Mar 17198,5335,1947,447341
31 Dec 16196,4982,0517,149392
30 Sep 16194,2672,0447,264392
30 Jun 16193,0712,3597,283392
31 Mar 16190,8842,2907,379392
31 Dec 15189,1312,2377,573392
30 Sep 15187,7162,0907,342392
30 Jun 15183,1151,9507,781392

Guadagni di qualità: MCK ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di MCK (1.2%) MCK sono più alti rispetto allo scorso anno (0.9%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: MCK è diventata redditizia negli ultimi 5 anni, aumentando i guadagni del 44.3% all'anno.

Accelerare la crescita: La crescita degli utili di MCK nell'ultimo anno ( 44.5% ) supera la media quinquennale ( 44.3% all'anno).

Guadagni vs Settore: La crescita degli utili MCK nell'ultimo anno ( 44.5% ) ha superato la percentuale del settore Healthcare 17%.

Rendimento del capitale proprio

ROE elevato: Le passività di MCK superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/06/10 04:38
Prezzo dell'azione a fine giornata2026/06/10 00:00
Utili2026/03/31
Utili annuali2026/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

McKesson Corporation è coperta da 32 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
David ToungArgus Research Company
Eric ColdwellBaird
Lawrence MarshBarclays